{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:02:24Z","timestamp":1751601744827,"version":"3.41.0"},"reference-count":0,"publisher":"Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo","issue":"2","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Peru Cardiol Cir Cardiovasc"],"abstract":"<jats:p>Introduction. Introduction. In Ecuador, there is limited data on the treatment of patients with heart failure (HF). Objective. This study aimed to determine the rate of use of prognosis-modifying drugs and their association with prognosis. Materials and methods. A retrospective observational study was conducted on patients with chronic HF included in the \u201cLos Ceibos\u201d registry between January 2017 and December 2022. Patients were followed for a median of 2.28 years (interquartile range [IQR]: 1.25-3.49). Results. A total of 711 patients diagnosed with HF were included. Among them, 82.7% (n=588) received angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor\u2013neprilysin inhibitors (ARNIs); 82.3% (n=585) received beta-blockers (BBs); and 51.3% (n=365) were treated with mineralocorticoid receptor antagonists (MRAs). Among patients with HFrEF, those receiving triple therapy (ACEI\/ARB\/ARNI + BB + MRA) had lower all-cause mortality compared to other groups (38.8%, log-rank p=0.014). In patients with Heart Failure with preserved Ejection Fraction (HFpEF), no mortality differences were observed according to the number of medications used (log-rank p=0.720). MRA use was not associated with a prognostic benefit in HFpEF (p&gt;0.05). Patients receiving triple therapy with ARNI + BB + MRA had better survival during follow-up compared to any other drug combination (log-rank p=0.027). Conclusions. A high rate of ACEI\/ARB\/ARNI and BB use was observed. The use of triple therapy, particularly the combination of ARNI + BB + MRA, was associated with improved prognosis in patients with HFrEF over a four-year follow-up period. No prognostic benefit of MRA use was observed in patients with HFpEF.<\/jats:p>","DOI":"10.47487\/apcyccv.v6i2.470","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T13:34:00Z","timestamp":1751031240000},"page":"75-82","source":"Crossref","is-referenced-by-count":0,"title":["Tratamiento farmacol\u00f3gico de pacientes con insuficiencia card\u00edaca cr\u00f3nica. Suban\u00e1lisis de un registro ecuatoriano","Pharmacological treatment of patients with chronic heart failure: a subanalysis of an ecuadorian registry"],"prefix":"10.47487","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2863-1907","authenticated-orcid":false,"given":"Luis","family":"Moreno-Rond\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-1454","authenticated-orcid":false,"given":"Mar\u00eda Elizabeth","family":"Ortega-Armas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1571-3672","authenticated-orcid":false,"given":"Diego","family":"Pulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2389-4812","authenticated-orcid":false,"given":"Robert","family":"Alarc\u00f3n Cede\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5197","authenticated-orcid":false,"given":"Juan","family":"D\u00edaz Heredia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2562-9062","authenticated-orcid":false,"given":"Diego","family":"Villavicencio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8198-5096","authenticated-orcid":false,"given":"Oscar","family":"Luces-Tejada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8073-8768","authenticated-orcid":false,"given":"Mario","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4208-1681","authenticated-orcid":false,"given":"Alex","family":"Castro-Mej\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"26947","published-online":{"date-parts":[[2025,6,27]]},"container-title":["Archivos Peruanos de Cardiolog\u00eda y Cirug\u00eda Cardiovascular"],"original-title":[],"link":[{"URL":"https:\/\/apcyccv.org.pe\/index.php\/apccc\/article\/download\/470\/663","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/apcyccv.org.pe\/index.php\/apccc\/article\/download\/470\/657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:00:24Z","timestamp":1751518824000},"score":1,"resource":{"primary":{"URL":"https:\/\/apcyccv.org.pe\/index.php\/apccc\/article\/view\/470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,27]]}},"URL":"https:\/\/doi.org\/10.47487\/apcyccv.v6i2.470","relation":{},"ISSN":["2708-7212"],"issn-type":[{"type":"electronic","value":"2708-7212"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}